blaC Resolved · high auto-curated

H37Rv Rv2068c · MTBC0 - · 307 aa · 2325886–2326809 H37Rv (-) · RefSeq NP_216584.1

Genomic neighbourhood (genome browser)

Open in full genome browser →

This gene (outlined) in its genomic context; arrows are neighbouring genes coloured by verdict. Click any gene to navigate. Pan and zoom in the full browser.

Annotation: from legacy to revised

Legacy (H37Rv / Mycobrowser)beta-lactamase
MTBC0 PGAP re-annotation—
Revised (this work)Beta-lactamase. Pfam: Beta-lactamase2 (PF13354.13), Beta-lactamase (PF00144.30).
Functional category (TubercuList)intermediary metabolism and respiration

Auto-curated: this verdict and function were generated by rules from PGAP + Pfam + Foldseek and have not been hand-reviewed.

Annotated on the H37Rv protein: this gene has no 1:1 ancestral MTBC0 anchor (PE/PPE, paralogue, IS element, or otherwise unanchored CDS).

In the literature (TB corpus sweep) 89 publications

89 TB publications mention this gene. 89 publications discuss this gene. Queried separately, 87 records carry a M. tuberculosis context and 12 a non-TB mycobacterial context (species named in the 12-record verified sample: M. abscessus (6), M. smegmatis (5), M. marinum (1)). The three counts come from three distinct PubMed queries (each with its own context filter), so they neither partition the total nor need to add up to it.

5 of 89: the most recently indexed records of the curated sweep at its date, not necessarily the most recent papers on this gene — the exhaustive list below is later and broader and may hold newer ones.
PublicationDate
Potential Drug Candidate for Inhibiting β -Lactamase Enzymes of Class A and Carbapenemase. doi:10.1007/s12088-025-01459-y 2026
Global whole-genome-based genomic insights into Mycobacterium tuberculosis: Clonal dominance, sequence-type structure, and antimicrobial resistance-virulence landscapes. doi:10.1016/j.meegid.2026.105894 2026
Mycobacterium tuberculosis fluorescent and bioluminescent imaging technologies: addressing the issue of sensitivity. doi:10.1080/17476348.2025.2581338 2026
Directed evolution of a beta-lactamase samples a wide variety of conformational states. doi:10.1002/pro.70322 2025
Strategic design of a multi-tier database for class A β-lactamase BlaC variants of M. tuberculosis: advancing the fight against antibacterial resistance. doi:10.1038/s41429-025-00862-3 2025
88 records returned by the alias sweep (a separate sweep from the 89 above; both are shown, neither is exhaustive)

Searched as: Rv2068c, blaC, Mb2094c, MMAR_3050, MAB_2875 — each in conjunction with a mycobacterial context term. Swept 2026-09-07.

PublicationJournalYear
Potential Drug Candidate for Inhibiting β -Lactamase Enzymes of Class A and Carbapenemase. doi:10.1007/s12088-025-01459-y Indian J Microbiol 2026
Global whole-genome-based genomic insights into Mycobacterium tuberculosis: Clonal dominance, sequence-type structure, and antimicrobial resistance-virulence landscapes. doi:10.1016/j.meegid.2026.105894 Infect Genet Evol 2026
Mycobacterium tuberculosis fluorescent and bioluminescent imaging technologies: addressing the issue of sensitivity. doi:10.1080/17476348.2025.2581338 Expert Rev Respir Med 2026
Directed evolution of a beta-lactamase samples a wide variety of conformational states. doi:10.1002/pro.70322 Protein Sci 2025
Strategic design of a multi-tier database for class A β-lactamase BlaC variants of M. tuberculosis: advancing the fight against antibacterial resistance. doi:10.1038/s41429-025-00862-3 names it J Antibiot (Tokyo) 2025
Structure and mechanism basis of β-lactam activity against Mycobacterium tuberculosis: A review of literature. doi:10.1016/j.ijtb.2025.01.001 Indian J Tuberc 2025
Comparative evaluation of five β-Lactamase inhibitors in combination with β-Lactams against multidrug-resistant Mycobacterium tuberculosis in vitro. doi:10.1186/s12879-025-10730-y BMC Infect Dis 2025
Stabilizing Mutations Enhance Evolvability of BlaC β-lactamase by Widening the Mutational Landscape. doi:10.1016/j.jmb.2025.168999 names it J Mol Biol 2025
Atypical Mycobacterium abscessus BlaRI Ortholog Mediates Regulation of Energy Metabolism but Not β-Lactam Resistance. doi:10.1111/mmi.15314 Mol Microbiol 2024
A low-barrier proton shared between two aspartates acts as a conformational switch that changes the substrate specificity of the β-lactamase BlaC. doi:10.1016/j.ijbiomac.2024.134665 names it Int J Biol Macromol 2024
Durlobactam, a Diazabicyclooctane β-Lactamase Inhibitor, Inhibits BlaC and Peptidoglycan Transpeptidases of Mycobacterium tuberculosis. doi:10.1021/acsinfecdis.4c00119 names it ACS Infect Dis 2024
Conserved proline residues prevent dimerization and aggregation in the β-lactamase BlaC. doi:10.1002/pro.4972 names it Protein Sci 2024
Positive epistasis drives clavulanic acid resistance in double mutant libraries of BlaC β-lactamase. doi:10.1038/s42003-024-05868-5 names it Commun Biol 2024
In silico design based on quantum chemical, molecular docking studies and ADMET predictions of ciprofloxacin derivatives as novel potential antibacterial and antimycrobacterium agents. doi:10.1080/07391102.2023.2240906 J Biomol Struct Dyn 2024
In vitro activity of new combinations of β-lactam and β-lactamase inhibitors against the Mycobacterium tuberculosis complex. doi:10.1128/spectrum.01781-23 Microbiol Spectr 2023
Mycobacterium tuberculosis β-lactamase variant reduces sensitivity to ampicillin/avibactam in a zebrafish-Mycobacterium marinum model of tuberculosis. doi:10.1038/s41598-023-42152-8 Sci Rep 2023
Heterogeneity in M. tuberculosis β-lactamase inhibition by Sulbactam. doi:10.1038/s41467-023-41246-1 Nat Commun 2023
Enhanced activity against a third-generation cephalosporin by destabilization of the active site of a class A beta-lactamase. doi:10.1016/j.ijbiomac.2023.126160 Int J Biol Macromol 2023
[In vitro activity of β-lactamase inhibitors avibanvctam and relebactam in combination with β-lactams against multidrug-resistant Mycobacterium tuberculosis and mutations of resistance genes]. doi:10.3760/cma.j.cn112147-20230111-00017 Zhonghua Jie He He Hu Xi Za Zhi 2023
Asp179 in the class A β-lactamase from Mycobacterium tuberculosis is a conserved yet not essential residue due to epistasis. doi:10.1111/febs.16892 FEBS J 2023
Heterogeneity in the M. tuberculosis β-Lactamase Inhibition by Sulbactam. doi:10.21203/rs.3.rs-2334665/v1 Res Sq 2023
Identification of drivers of mycobacterial resistance to peptidoglycan synthesis inhibitors. doi:10.3389/fmicb.2022.985871 Front Microbiol 2022
High-throughput fluorescent screening of β-lactamase inhibitors to improve antibiotic treatment strategies for tuberculosis. doi:10.1016/j.bios.2022.114606 Biosens Bioelectron 2022
Stabilization of Tuberculosis Reporter Enzyme Fluorescence (REFtb) Diagnostic Reagents for Use at the Point of Care. doi:10.3390/diagnostics12071745 Diagnostics (Basel) 2022
Uncovering Beta-Lactam Susceptibility Patterns in Clinical Isolates of Mycobacterium tuberculosis through Whole-Genome Sequencing. doi:10.1128/spectrum.00674-22 Microbiol Spectr 2022
Susceptibility of β-Lactam Antibiotics and Genetic Mutation of Drug-Resistant Mycobacterium tuberculosis Isolates in Korea. doi:10.4046/trd.2021.0175 Tuberc Respir Dis (Seoul) 2022
Penicillin Binding Proteins and β-Lactamases of Mycobacterium tuberculosis: Reexamination of the Historical Paradigm. doi:10.1128/msphere.00039-22 mSphere 2022
Variations in the SDN Loop of Class A Beta-Lactamases: A Study of the Molecular Mechanism of BlaC (Mycobacterium tuberculosis) to Alter the Stability and Catalytic Activity Towards Antibiotic Resistance of MBIs. doi:10.3389/fmicb.2021.710291 names it Front Microbiol 2021
The G132S Mutation Enhances the Resistance of Mycobacterium tuberculosis β-Lactamase against Sulbactam. doi:10.1021/acs.biochem.1c00168 Biochemistry 2021
Two β-Lactamase Variants with Reduced Clavulanic Acid Inhibition Display Different Millisecond Dynamics. doi:10.1128/AAC.02628-20 Antimicrob Agents Chemother 2021
Evaluating the covalent binding of carbapenems on BlaC using noncovalent interactions. doi:10.1007/s00894-021-04760-x names it J Mol Model 2021
Conserved residues Glu37 and Trp229 play an essential role in protein folding of β-lactamase. doi:10.1111/febs.15854 FEBS J 2021
Investigating β-Lactam Drug Targets in Mycobacterium tuberculosis Using Chemical Probes. doi:10.1021/acsinfecdis.0c00809 ACS Infect Dis 2021
A Fluorogenic Trehalose Probe for Tracking Phagocytosed Mycobacterium tuberculosis. doi:10.1021/jacs.0c07700 J Am Chem Soc 2020
β-Lactamase of Mycobacterium tuberculosis Shows Dynamics in the Active Site That Increase upon Inhibitor Binding. doi:10.1128/AAC.02025-19 Antimicrob Agents Chemother 2020
Rapid Tuberculosis Diagnosis Using Reporter Enzyme Fluorescence. doi:10.1128/JCM.01462-19 J Clin Microbiol 2019
Bis(benzoyl) phosphate inactivators of beta-lactamase C from Mtb. doi:10.1016/j.bmcl.2019.07.002 Bioorg Med Chem Lett 2019
Crystal Structure of Phosphoserine BlaC from Mycobacterium tuberculosis Inactivated by Bis(Benzoyl) Phosphate. doi:10.3390/ijms20133247 names it Int J Mol Sci 2019
Dual-Pharmacophore Pyrithione-Containing Cephalosporins Kill Both Replicating and Nonreplicating Mycobacterium tuberculosis. doi:10.1021/acsinfecdis.9b00112 ACS Infect Dis 2019
Tryptophan Fluorescence Quenching in β-Lactam-Interacting Proteins Is Modulated by the Structure of Intermediates and Final Products of the Acylation Reaction. doi:10.1021/acsinfecdis.9b00023 ACS Infect Dis 2019
Revisiting Anti-tuberculosis Therapeutic Strategies That Target the Peptidoglycan Structure and Synthesis. doi:10.3389/fmicb.2019.00190 Front Microbiol 2019
Evaluation of biochemical and molecular polymorphism in extended spectrum β-lactamases of Mycobacterium tuberculosis clinical isolates. doi:10.1016/j.ijtb.2018.04.012 Indian J Tuberc 2019
New Conformations of Acylation Adducts of Inhibitors of β-Lactamase from Mycobacterium tuberculosis. doi:10.1021/acs.biochem.8b01085 Biochemistry 2019
Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis. doi:10.1128/AAC.01489-18 Antimicrob Agents Chemother 2019
Molecular docking and dynamics of Nickel-Schiff base complexes for inhibiting β-lactamase of Mycobacterium tuberculosis. doi:10.1007/s40203-018-0044-6 In Silico Pharmacol 2018
Mechanistic investigation of resistance via drug-inactivating enzymes in Mycobacterium tuberculosis. doi:10.1080/03602532.2018.1533966 Drug Metab Rev 2018
Rapid and specific labeling of single live Mycobacterium tuberculosis with a dual-targeting fluorogenic probe. doi:10.1126/scitranslmed.aar4470 Sci Transl Med 2018
In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates. doi:10.1155/2018/3579832 Biomed Res Int 2018
Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence. doi:10.3791/56801 J Vis Exp 2018
Phosphate Promotes the Recovery of Mycobacterium tuberculosis β-Lactamase from Clavulanic Acid Inhibition. doi:10.1021/acs.biochem.7b00556 Biochemistry 2017
Search for non-lactam inhibitors of mtb β-lactamase led to its open shape in apo state: new concept for antibiotic design. doi:10.1038/s41598-017-06023-3 Sci Rep 2017
Efficacy of β-lactam/β-lactamase inhibitor combination is linked to WhiB4-mediated changes in redox physiology of Mycobacterium tuberculosis. doi:10.7554/eLife.25624 Elife 2017
Inhibition of β-lactamases of mycobacteria by avibactam and clavulanate. doi:10.1093/jac/dkw546 J Antimicrob Chemother 2017
Intravital excitation increases detection sensitivity for pulmonary tuberculosis by whole-body imaging with β-lactamase reporter enzyme fluorescence. doi:10.1002/jbio.201600132 J Biophotonics 2017
Real-time Imaging of Mycobacterium tuberculosis, Using a Novel Near-Infrared Fluorescent Substrate. doi:10.1093/infdis/jiw298 J Infect Dis 2017
New directions using reporter enzyme fluorescence (REF) as a tuberculosis diagnostic platform. doi:10.1016/j.tube.2016.09.009 Tuberculosis (Edinb) 2016
Routes of Synthesis of Carbapenems for Optimizing Both the Inactivation of L,D-Transpeptidase LdtMt1 of Mycobacterium tuberculosis and the Stability toward Hydrolysis by β-Lactamase BlaC. doi:10.1021/acs.jmedchem.6b00096 names it J Med Chem 2016
In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates. doi:10.1128/AAC.01035-15 Antimicrob Agents Chemother 2016
Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis. doi:10.1016/j.ijmyco.2014.10.018 Int J Mycobacteriol 2015
Quantitative detection of cells expressing BlaC using droplet-based microfluidics for use in the diagnosis of tuberculosis. doi:10.1063/1.4928879 names it Biomicrofluidics 2015
Kinetic and Structural Characterization of the Interaction of 6-Methylidene Penem 2 with the β-Lactamase from Mycobacterium tuberculosis. doi:10.1021/acs.biochem.5b00698 Biochemistry 2015
Hydrolysis of clavulanate by Mycobacterium tuberculosis β-lactamase BlaC harboring a canonical SDN motif. doi:10.1128/AAC.00598-15 names it Antimicrob Agents Chemother 2015
Inhibiting the β-Lactamase of Mycobacterium tuberculosis (Mtb) with Novel Boronic Acid Transition-State Inhibitors (BATSIs). doi:10.1021/acsinfecdis.5b00003 ACS Infect Dis 2015
Impact of β-lactamase inhibition on the activity of ceftaroline against Mycobacterium tuberculosis and Mycobacterium abscessus. doi:10.1128/AAC.05080-14 Antimicrob Agents Chemother 2015
Combinatorial active-site variants confer sustained clavulanate resistance in BlaC β-lactamase from Mycobacterium tuberculosis. doi:10.1002/pro.2617 names it Protein Sci 2015
Fluorogenic probes with substitutions at the 2 and 7 positions of cephalosporin are highly BlaC-specific for rapid Mycobacterium tuberculosis detection. doi:10.1002/anie.201405243 names it Angew Chem Int Ed Engl 2014
The PhoP-dependent ncRNA Mcr7 modulates the TAT secretion system in Mycobacterium tuberculosis. doi:10.1371/journal.ppat.1004183 PLoS Pathog 2014
Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β-lactamase from Mycobacterium tuberculosis. doi:10.1021/bi500339j Biochemistry 2014
Characterization of broad-spectrum Mycobacterium abscessus class A β-lactamase. doi:10.1093/jac/dkt410 J Antimicrob Chemother 2014
Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC lead to clavulanate resistance?: a biochemical rationale for the use of β-lactam-β-lactamase inhibitor combinations. doi:10.1128/AAC.01253-13 names it Antimicrob Agents Chemother 2013
Directed evolution of Mycobacterium tuberculosis β-lactamase reveals gatekeeper residue that regulates antibiotic resistance and catalytic efficiency. doi:10.1371/journal.pone.0073123 PLoS One 2013
Kinetic characterization of hydrolysis of nitrocefin, cefoxitin, and meropenem by β-lactamase from Mycobacterium tuberculosis. doi:10.1021/bi400177y Biochemistry 2013
Reappraising the use of β-lactams to treat tuberculosis. doi:10.1586/eri.12.96 Expert Rev Anti Infect Ther 2012
Rapid point-of-care detection of the tuberculosis pathogen using a BlaC-specific fluorogenic probe. doi:10.1038/nchem.1435 names it Nat Chem 2012
NXL104 irreversibly inhibits the β-lactamase from Mycobacterium tuberculosis. doi:10.1021/bi300508r Biochemistry 2012
Structures of the Michaelis complex (1.2 Å) and the covalent acyl intermediate (2.0 Å) of cefamandole bound in the active sites of the Mycobacterium tuberculosis β-lactamase K73A and E166A mutants. doi:10.1021/bi1015088 Biochemistry 2010
Biochemical and structural characterization of Mycobacterium tuberculosis beta-lactamase with the carbapenems ertapenem and doripenem. doi:10.1021/bi100232q Biochemistry 2010
Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. doi:10.1126/science.1167498 Science 2009
Genome-wide regulon and crystal structure of BlaI (Rv1846c) from Mycobacterium tuberculosis. doi:10.1111/j.1365-2958.2008.06583.x Mol Microbiol 2009
Identification of functional Tat signal sequences in Mycobacterium tuberculosis proteins. doi:10.1128/JB.00749-08 J Bacteriol 2008
Structure of the covalent adduct formed between Mycobacterium tuberculosis beta-lactamase and clavulanate. doi:10.1021/bi8001055 Biochemistry 2008
Molecular cloning, overexpression and biochemical characterization of hypothetical beta-lactamases of Mycobacterium tuberculosis H37Rv. doi:10.1111/j.1365-2672.2007.03721.x J Appl Microbiol 2008
Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate. doi:10.1021/bi701506h Biochemistry 2007
Beta-lactamase can function as a reporter of bacterial protein export during Mycobacterium tuberculosis infection of host cells. doi:10.1099/mic.0.2007/008516-0 Microbiology (Reading) 2007
Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics. doi:10.1128/AAC.00320-06 Antimicrob Agents Chemother 2006
The twin-arginine translocation pathway of Mycobacterium smegmatis is functional and required for the export of mycobacterial beta-lactamases. doi:10.1128/JB.187.22.7667-7679.2005 J Bacteriol 2005
Characterization of novel Mycobacterium tuberculosis and Mycobacterium smegmatis mutants hypersusceptible to beta-lactam antibiotics. doi:10.1128/JB.187.6.1892-1900.2005 J Bacteriol 2005
Genetic analysis of the beta-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to beta-lactam antibiotics. doi:10.1099/mic.0.27629-0 Microbiology (Reading) 2005

Title+abstract index only: a paper that names this gene solely in its body text, a figure legend or a supplement is invisible here. That is why this list sits beside the curated layer rather than replacing it - Rv0007's characterisation, found by a full-text sweep, returns zero in this one. Absence from this list is not absence from the literature. Source: PubMed E-utilities sweep (esearch + esummary), every alias of the gene searched in conjunction with a mycobacterial context term; ambiguous common-word aliases excluded. phase198, 2026-09-06.

This layer CITES the literature and adds context; it does not change the verdict or the function stated elsewhere in this fiche. This distinguishes a gene that is dark because nobody has looked from one that is dark despite having been studied. Source: PubMed (whole): H37Rv locus tag + GENE NAME + ortholog identifiers (Mb…, MMAR_…, MSMEG_…, ML…, MAB_…), under a mycobacterial context filter; hits verified against the abstract text. Species-context counts distinguish M. tuberculosis literature from literature on other mycobacteria. phase76/phase77, 2026-07-13.

Intrinsic disorder (sequence + structure) partially disordered

Predicted disorder16% of residues (metapredict) · mean AlphaFold pLDDT 91.9
Disordered regions1 IDR(s), longest 37 aa [0-37]

carries a substantial disordered region (37/307 residues); disorder is a property, not a function

A property (biophysics), not a function. No LLPS/condensate claim is made from disorder alone. Verdict unchanged. Source: metapredict v3 (Emenecker/Holehouse) per-residue disorder + AlphaFold mean pLDDT (annotation_mtbc P16.13).

CRISPRi vulnerability

Vulnerability index 0.73 (95% CI -1.14 to 3.50). A more negative index = more vulnerable to knockdown (better drug-target quality); indicative threshold VI ≤ -6 = highly vulnerable.

Quantitative CRISPRi knockdown, graded (finer than binary Tn-seq essentiality). Source: CRISPRi vulnerability index (Bosch 2021, supplementary Table S2 'mmc3.xlsx', bulk import via Europe PMC -- supersedes the per-gene pebble.rockefeller.edu scrape of phase46_crispri_vulnerability.py).

Caveat on this estimate. Bosch et al. flag this gene's vulnerability estimate as NOT certain, and here that call has a mechanical cause visible in the library itself: every guide targeting this gene is >=21 nt (str_span=0.298 on a 0-1 scale, near the genome floor), and guide repression strength saturates from 21 nt on -- so the library never sampled a partial knockdown for this gene, only the near-maximal repression plateau. The dose-response fit (and this VI) is therefore essentially unconstrained by data, not merely uncertain -- a limitation of the CRISPRi library design for the non-essential class (Bosch et al. 2021), not a defect in this specific measurement. n_guides=9 is descriptive only and does not predict this. Do not cite this VI as a standalone vulnerability claim.

Legacy record & comparison (Mycobrowser)

Mycobrowser functionHydrolyses beta-lactams to generate corresponding beta-amino acid [catalytic activity: a beta-lactam + H(2)O = a substituted beta-amino acid].
Mycobrowser EC 3.5.2.6 · agrees with the atlas

The legacy Mycobrowser record is shown for verification. Mycobrowser is no longer maintained; its EC numbers predate recent nomenclature revisions, so a class change usually reflects re-numbering, not a conflict.

Orthologues (reciprocal best hits across mycobacteria)

M. bovis Mb2094c · 100.0% identity
M. marinum MMAR_3050 · 67.0% identity
M. orygis RJtmp_002140 · 100.0% identity
M. abscessus MAB_2875 · 45.3% identity

Reciprocal-best-hit orthologues (DIAMOND) against the Mycobrowser reference proteomes. A missing species is informative: e.g. a gene absent from M. leprae was likely lost in its reductive genome evolution. Locus tags link to Mycobrowser.

Curated reference (UniProt)

UniProt P9WKD3 SwissProt · reviewed · Evidence at protein level
UniProt nameBeta-lactamase
EC (curated) EC 3.5.2.6
Curated functionExtended spectrum beta-lactamase (ESBL) that inactivates beta-lactam antibiotics by hydrolyzing the amide group of the beta-lactam ring. Displays high levels of penicillinase and cephalosporinase activity as well as measurable activity with carbapenems, including imipenem and meropenem. Plays a primary role in the intrinsic resistance of M.tuberculosis to beta-lactam antibiotics.

Functional vocabulary (eggNOG-mapper, orthology transfer)

COG category V Defense mechanisms
Preferred nameblaC
eggNOG descriptionbeta-lactamase
Orthologous groupCOG2367
EC number EC 3.5.2.6
KEGG orthology K17836
KEGG pathways map00311, map01130, map01501
KEGG modules M00627, M00628
Gene Ontology (47) GO:0003674, GO:0003824, GO:0005575, GO:0005576, GO:0005623, GO:0005886, GO:0006807, GO:0008150, GO:0008152, GO:0008800, GO:0009056, GO:0009308 +35 more

Orthology-based transfer (eggNOG 5.0.2, diamond). EC/KO/GO/CAZy are computed annotations, not manual curation; cross-check against the primary literature before treating a specific reaction as established.

Conservation & selection (intra-MTBC, 142 601 strains, snapshot of 2026-09-29)

pN/pS 0.119 · quasi-invariant (4 sites), pN/pS underpowered
Polymorphic sites (≥ 0.1% of strains) 3 synonymous, 1 missense, 0 nonsense, 0 frameshift

pN/pS from segregating SNPs (singletons removed) normalised by possible sites. Low pN/pS = purifying selection (a strong signal that a "hypothetical" is a real, constrained gene). A high pN/pS is ambiguous: relaxed constraint or positive selection (drug resistance, antigenic variation) inflate it; e.g. rpoB/katG/pncA score high here for resistance, not loss of function. A clonal disruption (one allele over a clade) suggests lineage pseudogenisation; a convergent one (many independent alleles) is typical of resistance loss-of-function.

Outgroup conservation (beyond the MTBC) Bacteria

Genus-wide presence (~53 non-MTBC Mycobacterium) present in 28/53 (53%) · mean identity 60.6% · 4/4 closest MTBAP relatives
conserved across the genus (present in 28/53 non-MTBC Mycobacterium genomes, incl. distant relatives) — an ancient core gene predating the genus radiation
Phylostratum (deepest detected homolog) MTBC-specific → Mycobacterium → Mycobacteriaceae → Corynebacteriales → Actinomycetia → Bacteria
detected in 4/13 non-Mycobacterium reference genomes (down to Bacteria) · mean identity 45.8%
detected down to outside the phylum (Proteobacteria/Firmicutes controls) — a universally conserved, ancient bacterial gene

Two orthogonal outgroup signals. M. canettii (the immediate outgroup) gives a deep-divergence dN/dS (a low value confirms a constrained, real gene; shown as confident only at ≥8 substitutions, else flagged low-power). Genus-wide presence/absence (tblastn vs assembled non-MTBC genomes) places the gene on the ancient-core ↔ MTBC-specific axis: a gene absent even from the closest MTBAP relatives is a candidate MTBC-specific innovation (possible host-adaptation factor, to confirm by synteny). The phylostratum extends that axis outside the genus (tblastn vs 13 reference genomes spanning Mycobacteriaceae → Corynebacteriales → Actinomycetia → outside the phylum): it is the deepest clade in which a homolog is still detected, i.e. a proxy for gene age. Read it with the null model in mind: a shallow (young) stratum can also reflect homology-detection failure for short or fast-evolving ORFs, so it is a descriptive axis, not a proof of novelty.

Essentiality (transposon mutagenesis)

DeJesus 2017 callNE · non-essential
What the call meansnon-essential
TA sites (Himar1) 15 in the ORF — 0 in the essential state, 0 growth-defect, 15 non-essential, 0 growth-advantage. Saturation 1.000, mean read count 281.333333333. A region of the protein devoid of TA sites is invisible to this assay: nothing can be inferred about it, in either direction.
All 15 sites lie in this ORF alone (no overlapping CDS shares any), so the call is attributable to this gene.

Genome-wide Himar1 transposon essentiality in H37Rv (DeJesus 2017). An essential call (ES/ESD/GD) is strong, independent evidence that a "hypothetical" locus encodes a functional, selectively required gene — orthogonal to intra-species conservation.

Conditional fitness (RB-TnSeq, 95 conditions) stress

ConditionGroupDirectionlog2 fitnesst
Meropenem stress mutant depleted (gene required) -2.883 -11.957
Ceftriaxone disodium salt hemi(heptahydrate) stress mutant depleted (gene required) -1.313 -8.384

Randomly-barcoded transposon screen across 95 carbon/nitrogen sources, pH, stressors and antibiotics (2 condition-specific phenotype(s) for this gene). A conditional fitness phenotype is a context lead, not a proven function, and never changes the verdict here. Note the blind spot: RB-TnSeq cannot measure essential genes. Source: RB-TnSeq 95-condition barcoded transposon screen, Mtb (PLoS Biol 2026, doi:10.1371/journal.pbio.3003529).

Mutant phenotypes (conditional Tn-seq, MtbTnDB)

Conditionlog2FCqEffect
altered fitness under Meropenem (drug exposure) -4.370.0 required

Conditional fitness of transposon-disruption mutants across 1 significant condition(s) (|log2FC|≥1, q≤0.05), from the standardized MtbTnDB compendium. A negative log2FC means the mutant is depleted — the gene contributes to fitness in that condition. An in-vivo defect for a "hypothetical" is strong evidence it matters for infection, even without a known molecular function. Disruption (Tn insertion), not a clean deletion; genetic-interaction screens excluded.

Proteomics (mass spectrometry) detected

MS detectiondetected in 14 of 16 independent MS datasets
Integrated abundance302.0 ppm · rank 638/3519 (81.9th percentile)

Detection by mass spectrometry is direct, experimental evidence that the protein product exists — orthogonal to sequence conservation and to Tn-seq essentiality, and especially decisive for a "hypothetical" locus. Read the dataset count as abundance, not as replication. Measured across this atlas (3,491 detected proteins), the number of datasets a protein appears in tracks its abundance almost monotonically: median 1.2 ppm at 1 dataset of 16, 27 ppm at 10, 392 ppm at 15, 1,325 ppm at 16 — three orders of magnitude. A high count therefore says the protein is abundant more than it says several independent experiments confirmed it. What the count does establish, at any value, is that the product exists.

Predicted localisation (DeepTMHMM + lipobox) lipoprotein

Predictionpredicted lipoprotein (lipobox + signal peptide)
DeepTMHMM classSP
Lipoboxsignal-peptidase-II lipobox; lipidated Cys near position 24

Transmembrane topology and signal peptide from DeepTMHMM (deep-learning reference predictor); lipoproteins from a (myco)bacterial lipobox motif. A sequence-based prediction of subcellular context.

Physico-chemical properties (computed, ProtParam)

Length307 aa
Molecular weight32.6 kDa
Theoretical pI5.77
GRAVY-0.091 (hydrophilic)
Aliphatic index87.2
Aromaticity0.062
Instability index33.7 (stable)

Computed from the ancestral MTBC0 sequence with the ExPASy ProtParam method (Biopython). Descriptive biophysical context: a positive GRAVY flags a hydrophobic (often membrane) protein, a high instability index (>40) predicts a short in-vitro half-life, an extreme pI hints at compartment or binding partner.

Domains (Pfam, hmmscan --cut_ga)

PfamAccessioni-EvalueResiduesDescription
Beta-lactamase2PF13354.13 1.7e-4444–299 Beta-lactamase enzyme family
Beta-lactamasePF00144.30 1.4e-2050–298 Beta-lactamase

3D structure (interactive — Mol*/pdbe-molstar)

Experimental structure 3zhh (PDBe), the strongest available structural evidence for this gene. Drag to rotate, scroll to zoom; hetero-groups (ligands, ions, waters hidden by default) shown as sticks.

Experimental structures (Protein Data Bank) 79 solved

PDBMethodResolutionCoverage
3zhh X-ray diffraction 2.85 Å 100%
6n14 X-ray diffraction 1.52169460473 Å 98%
7a74 X-ray diffraction 1.6 Å 98%
2gdn X-ray diffraction 1.72 Å 98%
6b6b X-ray diffraction 1.8 Å 98%
6b6d X-ray diffraction 1.8 Å 98%
6b6c X-ray diffraction 1.9 Å 98%
4q8i X-ray diffraction 1.901 Å 98%

Experimentally solved structures mapped from the UniProt accession via PDBe/SIFTS (79 total; up to 8 shown, ranked by sequence coverage then resolution). An experimental structure is direct proof of the folded product and the strongest structural evidence — superseding the predicted ESMFold/AlphaFold models below for any covered region.

Structural search (AlphaFold DB model, Foldseek vs PDB — genome-wide) pLDDT 91.9

PDB hitprobTM (aln)TM (query)TM (target)Seq. id.Cov. q / tE-valueDescription
4x6t-assembly1_A 1.00 0.99 0.85 0.99 99% 86% / 100% 1.2e-51 sig 4x6t-assembly1_A M.tuberculosis betalactamase complexed with inhibitor EC19
7a74-assembly1_A 1.00 0.99 0.86 0.99 100% 87% / 100% 1.7e-51 sig 7a74-assembly1_A Structure of G132N BlaC from Mycobacterium tuberculosis
7a5w-assembly1_A 1.00 1.00 0.86 0.99 100% 86% / 100% 3.2e-51 sig 7a5w-assembly1_A Structure of D172N BlaC from Mycobacterium tuberculosis
6h27-assembly2_B 1.00 1.00 0.86 0.98 100% 86% / 98% 7.1e-51 sig 6h27-assembly2_B Structure of S70C BlaC from Mycobacterium tuberculosis
3ny4-assembly1_A 1.00 0.99 0.86 0.99 100% 86% / 100% 6.7e-51 sig 3ny4-assembly1_A Crystal Structure of BlaC-K73A bound with Cefamandole

Foldseek search of the AlphaFold DB model (mean pLDDT 91.9, gated at 70) against the PDB — a genome-wide extension of the ESMFold dark-gene search that also covers proteins beyond the single-sequence length limit. Confident structural neighbours (E < 0.01) shown.

Genomic context (neighbours & predicted operon) operon of 2

Upstream (5' on genome)Rv2067c (- strand, 15 bp gap)
Downstream (3' on genome)sigC (+ strand, 134 bp gap)
Predicted operon Rv2067c · blaC

Neighbours from the H37Rv annotation (- strand). The operon is predicted by co-directional intergenic distance (same strand, gaps ≤50 bp) — a transcription-unit hypothesis, not a mapped TSS. For a "hypothetical", co-transcription with a characterised operon is a concrete functional lead (complements the STRING neighborhood channel below).

Published operon evidence (two independent sources)

Roback 2007 (logistic regression: distance + expression correlation, 474 microarrays) operon of 2: Rv2067c · blaC — agrees with the distance heuristic above
REMap 2016 (RNA-seq coverage continuity, CDC1551, tag MT2128) exponential phase: operon of 2, Rv2067c · Rv2068c (coverage 50.05)
expressed, no multi-gene operon (stationary phase, coverage 13.72) — agrees with the distance heuristic above

Two independent published operon maps, cited alongside the distance heuristic above: an association corroborating or contradicting the heuristic, never proof of shared function. REMap's RNA-seq coverage continuity is the most direct of the three signals; Roback's logistic regression and the intergenic-distance heuristic are statistical proxies.

Transcriptional regulation (signed TRN: ChIP-seq + TFOE)

Regulated by (1 TF) Rv1353c (represses)

Regulatory edges from the ISB signed transcriptional regulatory network (TF ChIP-seq binding, Minch 2015 + TF-overexpression response, Rustad 2014). An edge is regulatory evidence (binding and/or expression change), not necessarily direct. For a "hypothetical", membership in a known regulon (e.g. DosR dormancy, PhoP virulence) is a physiological-context lead, not a function.

Condition: Condition-blind by construction. These edges come from transcription-factor OVEREXPRESSION in a single laboratory condition, so a listed regulator is not a claim that it governs this gene in every circumstance. Measured counter-examples exist within this atlas (see Rv2516c, where the DosR regulon collapses under moxifloxacin while the gene itself rises). Read a regulator as 'capable of shifting this gene', and look for the condition before building a hypothesis on it.

Functional interaction network (STRING v12, guilt-by-association)

Explore full network →

Node colour = verdict, dashed = still uncharacterised; edge colour = evidence (green experimental, orange genomic-context, grey co-expression), width ∝ score. Click a partner to open its page; "Explore full network" to walk the graph.

Closest characterised functional partner: Rv2067c (hypothetical protein), high confidence (score 777, all STRING channels except text-mining; the partner is chosen on its genomic-context evidence).

Showing the 15 strongest of this gene's 19 partners at medium confidence (3 at high confidence). The table is an extract, not a neighbourhood: across the proteome the real median degree is 34 while the served median is 15, so no hub, degree distribution or centrality may be read on this table. None of the 19 partners rests on an interaction measured in M. tuberculosis itself.

PartnerProductScoreNo text-miningChannels (≥400)
Rv2067c hypothetical protein 778 777 ctx neighborhood:772
Rv2069 sigC ECF RNA polymerase sigma factor SigC 663 655 ctx neighborhood:589
Rv2782c pepR zinc protease 546 547 ctx neighborhood:544
Rv2783c gpsI bifunctional guanosine pentaphosphate synthetase/polyribonucleotide nucleotidyltransferase 478 478 ctx neighborhood:473
Rv3044 fecB FeIII-dicitrate-binding periplasmic lipoprotein 442 254
Rv3364c hypothetical protein 706 195 textmining:651
Rv1923 lipD lipase LipD 705 182 textmining:655
Rv1497 lipL esterase LipL 525 166 textmining:455
Rv3354 hypothetical protein 464 62 textmining:453
Rv3775 lipE lipase LipE 406 57
Rv3627c dacB hypothetical protein 411 54 textmining:403
Rv3763 lpqH lipoprotein LpqH 541 49 textmining:538
Rv3677c beta lactamase 460 49 textmining:456
Rv1922 lipoprotein 400 48
Rv0406c beta lactamase-like protein 531 46 textmining:529

STRING combines evidence channels (neighborhood, fusion, cooccurrence, coexpression, experimental, database, text-mining) into a 0–1000 score. The ctx badge marks edges carried by the genomic-context channels (conserved neighborhood, fusion, phylogenetic co-occurrence), which are independent of orthology and structure and the strongest signal for an unknown gene. The no text-mining column recomputes the score from data alone, so a link that does not depend on the literature is visible. Association is a function hypothesis, not proof: corroborate with the operon context and the primary literature before assigning a function.

Where the experimental evidence comes from, and why it matters here. STRING's experimental channel fuses interactions measured in M. tuberculosis with interactions measured in another organism and transferred to this pair by orthology. The two are not equivalent for this atlas, whose standing rule is that better studied elsewhere is not a function established in M. tuberculosis. Measured on the served network: of the 38 229 partner pairs shown across the atlas, 13 483 partner rows carry a non-zero experimental channel, and only 106 pairs rest on an interaction measured in M. tuberculosis itself — 0.3 % of the network. Those 106 are long-established complexes (ESX-1/ESAT-6, RNA polymerase with CarD and RbpA, the Pup–Mpa proteasome, gyrase, Emb, GarA with PknB and PknG, the Rel modules); no still-uncharacterised gene is among them. The reason is not a gap in this atlas but in the literature: there is almost no experimental interactome of this bacterium, IntAct holding 134 curated protein pairs for a ~4 000-gene proteome. A exp (transferred) badge is therefore a lead, never a measurement, and an absence of badge is not evidence that the pair does not interact.

Evidence

  • Annotation from H37Rv (no MTBC0 1:1 anchor; H37Rv protein used): beta-lactamase
  • Pfam (hmmscan --cut_ga): Beta-lactamase2 PF13354.13 (E=2e-44), Beta-lactamase PF00144.30 (E=1e-20)
  • (auto-curated by rules from PGAP + Pfam + Foldseek; not hand-reviewed)

Sources

  • Ancestral sequence & coordinates: Harrison LB et al. (2024), An imputed ancestral reference genome for the MTBC, doi:10.1101/2023.09.07.556366
  • Product annotation: NCBI PGAP on MTBC0; legacy from H37Rv NC_000962.3 (RefSeq NP_216584.1)
  • Domains: Pfam-A via hmmscan --cut_ga — Beta-lactamase2 (PF13354.13), Beta-lactamase (PF00144.30)
  • Sequence-level signal: ESM Atlas (EvolutionaryScale × BioHub) — exploratory
  • Controlled vocabulary: eggNOG-mapper 2.1.12 (Cantalapiedra et al. 2021, doi:10.1093/molbev/msab293), eggNOG 5.0 DB (Huerta-Cepas et al. 2019) — OG COG2367
  • Curated reference: UniProt P9WKD3 (SwissProt, reviewed; Evidence at protein level)
  • Intra-MTBC selection: pN/pS and disruption from SPDI variants of 142 601 MTBC strains (this work, local collection vs H37Rv NC_000962.3)
  • Genome-wide structure: AlphaFold DB model (Jumper et al. 2021, doi:10.1038/s41586-021-03819-2; Varadi et al. 2024, doi:10.1093/nar/gkad1011) searched vs PDB with Foldseek (mean pLDDT 91.9)
  • Interaction network: STRING v12.0 (Szklarczyk et al. 2023, doi:10.1093/nar/gkac1000), taxon 83332, CC-BY 4.0 — 19 functional partner(s); context anchor Rv2067c
  • Essentiality: genome-wide transposon mutagenesis in H37Rv — DeJesus et al. 2017 (mBio, doi:10.1128/mBio.02133-16, CC BY)
  • Proteomics: integrated mass-spectrometry abundance from PaxDb 5.0 (Huang et al. 2023, doi:10.1016/j.mcpro.2023.100640), taxon 83332 — weighted average of 16 datasets, incl. Schubert et al. 2013 (doi:10.1016/j.chom.2013.04.008) and Albrethsen et al. 2013 (doi:10.1074/mcp.M112.018846)
  • Functional category: TubercuList scheme (Cole et al. 1998, doi:10.1038/31159), via Mycobrowser (Kapopoulou et al. 2011, doi:10.1016/j.tube.2010.09.006)
  • Orthologues: reciprocal best hits (DIAMOND, Buchfink et al. 2021, doi:10.1038/s41592-021-01101-x) against Mycobrowser release 5 reference proteomes
  • Experimental structures: PDBe/SIFTS UniProt→PDB mapping (Dana et al. 2019, doi:10.1093/nar/gky1114)
  • Genomic context / operon: H37Rv annotation; operon predicted by co-directional intergenic distance (Salgado et al. 2000, doi:10.1073/pnas.030539397)
  • Transcriptional regulation: ISB signed TRN — TF ChIP-seq (Minch et al. 2015, doi:10.1038/ncomms6829) + TF overexpression (Rustad et al. 2014, doi:10.1186/gb-2014-15-11-502)
  • Mutant phenotypes: standardized Tn-seq compendium MtbTnDB (Jinich et al. 2025, doi:10.1111/mmi.15370), aggregating many primary Tn-seq studies across conditions
  • Physico-chemical properties: ExPASy ProtParam method via Biopython (Gasteiger et al. 2005), computed from the MTBC0 sequence
  • Predicted localisation: DeepTMHMM (Hallgren et al. 2022, doi:10.1101/2022.04.08.487609) for transmembrane topology and signal peptide; (myco)bacterial lipobox (Sutcliffe & Harrington 2004, doi:10.1099/mic.0.26804-0)
  • Primary literature: none located yet; annotation rests on the domain/homology sources above.

Ancestral MTBC0 protein sequence

>H37Rv|Rv2068c|blaC
MRNRGFGRRELLVAMAMLVSVTGCARHASGARPASTTLPAGADLADRFAELERRYDARLGVYVPATGTTAAIEYRADERFAFCSTFKAPLVAAVLHQNPLTHLDKLITYTSDDIRSISPVAQQHVQTGMTIGQLCDAAIRYSDGTAANLLLADLGGPGGGTAAFTGYLRSLGDTVSRLDAEEPELNRDPPGDERDTTTPHAIALVLQQLVLGNALPPDKRALLTDWMARNTTGAKRIRAGFPADWKVIDKTGTGDYGRANDIAVVWSPTGVPYVVAVMSDRAGGGYDAEPREALLAEAATCVAGVLA